Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H41N3O10S2 |
Molecular Weight | 703.823 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC3=CC=C(OCC4=CSC(C)=N4)C=C3)[C@H](O)CN(CC(C)C)S(=O)(=O)C5=CC=C6OCOC6=C5
InChI
InChIKey=JORVRJNILJXMMG-OLNQLETPSA-N
InChI=1S/C33H41N3O10S2/c1-20(2)14-36(48(39,40)25-8-9-29-30(13-25)45-19-44-29)15-28(37)27(35-33(38)46-31-17-43-32-26(31)10-11-41-32)12-22-4-6-24(7-5-22)42-16-23-18-47-21(3)34-23/h4-9,13,18,20,26-28,31-32,37H,10-12,14-17,19H2,1-3H3,(H,35,38)/t26-,27-,28+,31-,32+/m0/s1
Brecanavir (previously known as VX-385), a HIV aspartyl protease inhibitor was developed for the treatment of HIV. The inhibition of HIV viral proteinase enzyme prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Brecanavir reached Phase II development. However, GlaxoSmithKline announced to discontinue development brecanavir. Because of the inability to develop a viable oral dosage formulation capable of delivering the desired brecanavir levels in patients with multi-drug resistant HIV.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. | 2004 Nov 16 |
|
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. | 2006 Apr 1 |
|
Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. | 2006 Jun |
|
In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. | 2006 Mar |
|
Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. | 2007 Apr |
|
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006. | 2007 Jul |
|
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. | 2007 Sep |
|
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. | 2007 Sep 28 |
|
Recent developments of peptidomimetic HIV-1 protease inhibitors. | 2011 |
|
GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions. | 2014 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16723584
In part 1 of the study, single oral doses of Brecanavir (BCV) ranged from 25 mg to 800 mg. In part 2, single oral doses of BCV ranged from 10 mg to 300 mg and were coadministered with 100-mg oral ritonavir (RTV) soft gel capsules. Single doses of BCV and BCV/RTV were generally well tolerated. There were no severe adverse events (SAEs), and no subject was withdrawn due to BCV.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C97366
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
313682-08-5
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
E367I8C7FI
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
C76908
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
C512121
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL206031
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
RR-60
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
SUB33558
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
DB04887
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
100000127502
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
5743186
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
DTXSID10185296
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
8705
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY | |||
|
BRECANAVIR
Created by
admin on Fri Dec 15 16:08:48 GMT 2023 , Edited by admin on Fri Dec 15 16:08:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY